ReviewExpert review of neurotherapeutics2011
Corticosteroid use in neurocysticercosis.
Review in Expert review of neurotherapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 66 citations in OpenAlex.
- Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after.Epilepsia · 2014Trial
- Comparative analysis of parenchymal and extraparenchymal neurocysticercosis: a 10-year experience from northern Thailand.BMC infectious diseases · 2026Article
- Taenia solium neurocysticercosis: Its current epidemiological, diagnostic, therapeutic, and control landscapes.PLoS neglected tropical diseases · 2026Review
- Neurocysticercosis Is the Result of the Interplay between Parasites, Hormones, and Inflammation.Neuroimmunomodulation · 2026Review
- Obstructive hydrocephalus: when subarachnoid cysts alert to the challenging diagnosis of neurocysticercosis.Quantitative imaging in medicine and surgery · 2025Article
- Ivermectin as a promising therapeutic option for onchocerciasis-associated epilepsy.Epilepsia open · 2025Review
- Murine Extraparenchymal Neurocysticercosis: Appropriate Model for Evaluating Anthelminthic and Anti-Inflammatory Treatment Schedules.Tropical medicine and infectious disease · 2024Article
- Transcriptomic analysis of subarachnoid cysts of Taenia solium reveals mechanisms for uncontrolled proliferation and adaptations to the microenvironment.Scientific reports · 2024Article
- Article
- Human Neurocysticercosis: An Overview.Pathogens (Basel, Switzerland) · 2022Review
- Community-level prevalence of epilepsy and of neurocysticercosis among people with epilepsy in the Balaka district of Malawi: A cross-sectional study.PLoS neglected tropical diseases · 2022Article
- Neurocysticercosis. A frequent cause of seizures, epilepsy, and other neurological morbidity in most of the world.Journal of the neurological sciences · 2021Review
- Current Diagnostic Criteria for Neurocysticercosis.Research and reports in tropical medicine · 2021Review
- Subarachnoid neurocysticercosis: emerging concepts and treatment.Current opinion in infectious diseases · 2020Review
- Population Screening for Urine Antigens to Detect Asymptomatic Subarachnoid Neurocysticercosis: A Pilot Study in Northern Peru.The American journal of tropical medicine and hygiene · 2020Article
- Unique Characteristics of Epilepsy Development in Neurocysticercosis.The American journal of tropical medicine and hygiene · 2020Review
- Taenia solium Cysticercosis and Its Impact in Neurological Disease.Clinical microbiology reviews · 2020Review
- Natural History of Treated Subarachnoid Neurocysticercosis.The American journal of tropical medicine and hygiene · 2020Article
- Controlling the Host Response in Neurocysticercosis.The American journal of tropical medicine and hygiene · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The cystic larvae of Taenia solium commonly infect the human nervous system, resulting in neurocysticercosis, a major contributor to seizure disorders in most of the world. Inflammation around the parasites is a hallmark of neurocysticercosis pathophysiology. Although mechanisms regulating this inflammation are poorly understood, anti-inflammatory drugs, particularly corticosteroids, have been long used alone or with anthelmintics to manage disease and limit neurological complications and perhaps damage to neural tissues. Only scarce controlled data exist to determine when and what type of corticosteroids and the treatment regime to use. This article revisits the mechanisms of action, rationale, evidence of benefit, safety and problems of corticosteroids in the context of neurocysticercosis, as well as alternative anti-inflammatory strategies to limit the damage caused by inflammation in the CNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.